Professor Robert Liwski
Dr. Robert Liwski is the Medical Director of the HLA Laboratory at the Queen Elizabeth II Hospital and Professor of Pathology at Dalhousie University in Halifax, Canada. He is also the Medical and Scientific Director of the HLA Laboratory at the Canadian Blood Services Head Office in Ottawa. Dr. Liwski obtained his PhD in Transplantation Immunology in 1999, his MD degree in 2003 and completed his fellowship training in Hematological Pathology in 2006, all at Dalhousie University. He joined the American Society for Histocompatibility and Immunogenetics (ASHI) in 2010 and completed ASHI Director training program in 2012. Within ASHI Dr. Liwski serves on the Board of Directors (member), Proficiency Testing committee (co-chair) and the Director Training Review and Credentialing (DTRC) committee (member). His research interests include transplantation immunology, ischemia reperfusion injury and optimization of diagnostic testing in transplantation. Dr. Liwski has developed several optimized HLA antibody testing methods including the Halifax/Halifaster flow crossmatch protocols and the Rapid Optimized Single Antigen Bead (ROB) assay. He was awarded the Canadian Association of Pathologists Junior Scientist Award for his research investigating the role of activated protein C in prevention of ischemia reperfusion injury and cancer metastasis.